Metabolic Risk Panel
Test Code
39447
80061, 82172, 83036, 83525, 84681
CPT Code is subject to a Medicare Limited Coverage Policy and may require a signed ABN when ordering.
Clinical Significance
Metabolic Risk Panel - This panel is for early assessment of metabolic risk, using carefully selected tests that identify early metabolic deviations indicating disease risk. This panel has been selected to identify physiological changes oftentimes evident before the manifestation of common metabolic syndrome risk factors, to aid practitioners in identifying risk and delaying or preventing disease progression.
Test Details
Cardio IQ® Cholesterol, Total
Cardio IQ® HDL Cholesterol
Cardio IQ® Triglycerides
Cardio IQ® Non-HDL and Calculated Components
Cardio IQ® Apolipoprotein B
Cardio IQ® Hemoglobin A1c
Insulin, Intact, LC/MS/MS
C-Peptide, LC/MS/MS and IR Score
Cardio IQ® HDL Cholesterol
Cardio IQ® Triglycerides
Cardio IQ® Non-HDL and Calculated Components
Cardio IQ® Apolipoprotein B
Cardio IQ® Hemoglobin A1c
Insulin, Intact, LC/MS/MS
C-Peptide, LC/MS/MS and IR Score
If a cholesterol measurement is to be performed along with triglycerides, but not part of a lipid panel, then the patient should be fasting 9-12 hours prior to collection. If the cholesterol is ordered as part of a lipid panel, then a fasting sample is not required.
The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
The assay manufacturer Beckman Coulter advises: N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been determined to interfere with assays for cholesterol and uric acid where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
Methodology
Spectrophotometry (SP) • Enzymatic • Immunoassay (IA) • Immunocapture • Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)
Reference Range(s)
See Laboratory Report
Alternative Name(s)
Met Risk Panel,Cardiometabolic Risk Panel
Preferred Specimen(s)
2.5 mL serum and 1 mL whole blood collected in an EDTA (lavender-top) tube
Minimum Volume
1.4 mL serum • 0.5 mL whole blood
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
- Room temperature: 24 hours
- Refrigerated: 7 days
- Frozen: 28 days
Reject Criteria
Hemolysis • Grossly lipemic • Moderate to grossly icteric • Whole blood other than EDTA (lavender-top)
Setup Schedule
2.5 mL serum and 1 mL whole blood collected in an EDTA (lavender-top) tube
1.4 mL serum • 0.5 mL whole blood
Refrigerated (cold packs)
Room temperature: 24 hours
Refrigerated: 7 days
Frozen: 28 days
Refrigerated: 7 days
Frozen: 28 days
Hemolysis • Grossly lipemic • Moderate to grossly icteric • Whole blood other than EDTA (lavender-top)